Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Dr. Sarina Elmariah explores the complex systemic burden of PN, from diverse clinical presentations and delayed diagnosis to the profound impact of itch, sleep disruption, comorbidities, and reduced quality of life.
Join experts Roland Buhl, Joaquim Mullol, and Giselle Mosnaim as they discuss the role of type 2 inflammation across the unified airway, with a focus on the amplified burden and the difficulty controlling inflammation when asthma and CRSwNP coexist.

Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.
Join Drs. Sarina Elmariah and Pedro Bastos to explore the full systemic burden of prurigo nodularis, looking beyond the nodules to discover how real-world evidence for approved biologics can inform treatment decisions and long-term care across diverse patient populations.
Drs. Sarina Elmariah and Pedro Bastos led an engaging ADVENT Industry Hub at EADV 2026 in Vienna, Austria, exploring the full systemic burden of prurigo nodularis (PN) beyond its visible nodules. The session highlighted how real-world evidence for approved biologics can inform treatment decisions and support long-term disease management across diverse patient populations.
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.